Microbial isolation and emergence of antimicrobial resistance associated with tigecycline usage

Slover, 2007, Tigecycline: a novel broad-spectrum antimicrobial, Ann Pharmacother, 4, 965, 10.1345/aph.1H543 Falagas, 2009, Tigecycline for the treatment of patients with community-acquired pneumonia requiring hospitalization, Expert Rev Anti Infect Ther, 7, 913, 10.1586/eri.09.73 Poulakou, 2009, Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens, J Infect, 58, 273, 10.1016/j.jinf.2009.02.009 Belvisi, 2009, Successful treatment of Stenotrophomonas maltophilia soft tissue infection with tigecycline: A case report, J Chemother, 2, 367, 10.1179/joc.2009.21.3.367 Hawser, 2010, Activity of tigecycline against recent European clinical isolates of Clostridium difficile, Int J Antimicrob Agents, 35, 97, 10.1016/j.ijantimicag.2009.09.009 Bhattacharya, 2009, Tigecycline, J Postgrad Med, 55, 65, 10.4103/0022-3859.48443 Lautenbach, 2001, Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes, Clin Infect Dis, 32, 1162, 10.1086/319757 Peña, 2007, Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients, Antimicrob Agents Chemother, 51, 1967, 10.1128/AAC.01483-06 Hornsey, 2010, Emergence of AcrAB-mediated tigecycline resistance in a clinical isolate of Enterobacter cloacae during ciprofloxacin treatment, Int J Antimicrob Agents, 35, 478, 10.1016/j.ijantimicag.2010.01.011 Daly, 2007, Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae, Pharmacotherapy, 27, 1052, 10.1592/phco.27.7.1052 Horan, 2008, CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting, Am J Infect Control, 36, 309, 10.1016/j.ajic.2008.03.002 Garner, 1996 CLSI, 2010 Kronvall, 2006, Epidemiological MIC cut-off values for tigecycline calculated from Etest MIC values using normalized resistance interpretation, J Antimicrob Chemother, 57, 498, 10.1093/jac/dki489 Nord, 2006, Effect of tigecycline on normal oropharyngeal and intestinal microflora, Antimicrob Agents Chemother, 50, 3375, 10.1128/AAC.00373-06 Takeuchi, 2009, Susceptible bacteria increased with limited usage of antibiotics: Data with emphasis on defined daily doses, Pediatr Int, 51, 696, 10.1111/j.1442-200X.2009.02847.x García-Cabrera, 2010, Superinfection during treatment of nosocomial infections with tigecycline, Eur J Clin Microbiol Infect Dis, 29, 867, 10.1007/s10096-010-0942-y Frampton, 2005, Tigecycline, Drugs, 65, 2623, 10.2165/00003495-200565180-00008 Blot, 2007, Candida peritonitis, Curr Opin Crit Care, 13, 195, 10.1097/MCC.0b013e328028fd92 Samonis, 2006, Comparative effects of ertapenem, imipenem, and meropenem on the colonization of the gastrointestinal tract of mice by Candida albicans, Med Mycol, 44, 233, 10.1080/13693780500395225 Samonis, 2008, Effects of tigecycline and daptomycin on murine gut colonization by Candida albicans, Mycoses, 51, 324, 10.1111/j.1439-0507.2008.01500.x Papaparaskevas, 2010, In vitro activity of tigecycline against 2423 clinical isolates and comparison of the available interpretation breakpoints, Diagn Microbiol Infect Dis, 66, 187, 10.1016/j.diagmicrobio.2009.09.012 2009 Crandon, 2009, Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs, J Antimicrob Chemother, 64, 837, 10.1093/jac/dkp301 Cui, 2010, Mutant prevention concentration of tigecycline for carbapenem-susceptible and -resistant Acinetobacter baumannii, J Antibiot (Tokyo), 63, 29, 10.1038/ja.2009.111 Karageorgopoulos, 2008, Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: A review of the scientific evidence, J Antimicrob Chemother, 62, 45, 10.1093/jac/dkn165